ID   NMDE2_HUMAN             Reviewed;        1484 AA.
AC   Q13224; Q12919; Q13220; Q13225; Q14CU4; Q9UM56;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2001, sequence version 3.
DT   28-JUN-2023, entry version 219.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 2B;
DE            Short=GluN2B;
DE   AltName: Full=Glutamate [NMDA] receptor subunit epsilon-2;
DE   AltName: Full=N-methyl D-aspartate receptor subtype 2B;
DE            Short=NMDAR2B {ECO:0000303|PubMed:7959773};
DE            Short=NR2B;
DE   AltName: Full=N-methyl-D-aspartate receptor subunit 3;
DE            Short=NR3;
DE            Short=hNR3 {ECO:0000303|PubMed:7999784};
DE   Flags: Precursor;
GN   Name=GRIN2B; Synonyms=NMDAR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-407.
RC   TISSUE=Fetal brain;
RX   PubMed=7999784; DOI=10.1016/0167-4781(94)00189-a;
RA   Adams S.L., Foldes R.L., Kamboj R.K.;
RT   "Human N-methyl-D-aspartate receptor modulatory subunit hNR3: cloning and
RT   sequencing of the cDNA and primary structure of the protein.";
RL   Biochim. Biophys. Acta 1260:105-108(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RC   TISSUE=Fetal brain;
RX   PubMed=8768735;
RA   Hess S.D., Daggett L.P., Crona J., Deal C., Lu C.-C., Urrutia A.,
RA   Chavez-Noriega L., Ellis S.B., Johnson E.C., Velicelebi G.;
RT   "Cloning and functional characterization of human heteromeric N-methyl-D-
RT   aspartate receptors.";
RL   J. Pharmacol. Exp. Ther. 278:808-816(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Mandich P., Schito A.M., Pizzuti A., Ratti A.;
RT   "Cloning of GRIN2B human subunit.";
RL   Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-294 AND 661-1089.
RX   PubMed=7959773; DOI=10.1006/geno.1994.1366;
RA   Mandich P., Schito A.M., Bellone E., Antonacci R., Finelli P., Rocchi M.,
RA   Ajmar F.;
RT   "Mapping of the human NMDAR2B receptor subunit gene (GRIN2B) to chromosome
RT   12p12.";
RL   Genomics 22:216-218(1994).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=9547169; DOI=10.1016/s0304-3940(97)00853-7;
RA   Schito A.M., Pizzuti A., Di Maria E., Schenone A., Ratti A., Defferrari R.,
RA   Bellone E., Mancardi G.L., Ajmar F., Mandich P.;
RT   "mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate
RT   (NMDA) receptor subunit.";
RL   Neurosci. Lett. 239:49-53(1997).
RN   [7]
RP   INTERACTION WITH MAGI3.
RX   PubMed=10748157; DOI=10.1074/jbc.m909741199;
RA   Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.;
RT   "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3,
RT   a novel membrane-associated guanylate kinase.";
RL   J. Biol. Chem. 275:21477-21485(2000).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND PRR7, AND INTERACTION WITH PRR7.
RX   PubMed=27458189; DOI=10.15252/embj.201593070;
RA   Kravchick D.O., Karpova A., Hrdinka M., Lopez-Rojas J., Iacobas S.,
RA   Carbonell A.U., Iacobas D.A., Kreutz M.R., Jordan B.A.;
RT   "Synaptonuclear messenger PRR7 inhibits c-Jun ubiquitination and regulates
RT   NMDA-mediated excitotoxicity.";
RL   EMBO J. 35:1923-1934(2016).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATIONS, VARIANT MRD6 CYS-682, AND CHARACTERIZATION OF
RP   VARIANT MRD6 CYS-682.
RX   PubMed=20890276; DOI=10.1038/ng.677;
RA   Endele S., Rosenberger G., Geider K., Popp B., Tamer C., Stefanova I.,
RA   Milh M., Kortum F., Fritsch A., Pientka F.K., Hellenbroich Y.,
RA   Kalscheuer V.M., Kohlhase J., Moog U., Rappold G., Rauch A., Ropers H.H.,
RA   von Spiczak S., Tonnies H., Villeneuve N., Villard L., Zabel B., Zenker M.,
RA   Laube B., Reis A., Wieczorek D., Van Maldergem L., Kutsche K.;
RT   "Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA
RT   receptors cause variable neurodevelopmental phenotypes.";
RL   Nat. Genet. 42:1021-1026(2010).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=26919761; DOI=10.1021/acs.jmedchem.5b02010;
RA   Volgraf M., Sellers B.D., Jiang Y., Wu G., Ly C.Q., Villemure E.,
RA   Pastor R.M., Yuen P.W., Lu A., Luo X., Liu M., Zhang S., Sun L., Fu Y.,
RA   Lupardus P.J., Wallweber H.J., Liederer B.M., Deshmukh G., Plise E.,
RA   Tay S., Reynen P., Herrington J., Gustafson A., Liu Y., Dirksen A.,
RA   Dietz M.G., Liu Y., Wang T.M., Hanson J.E., Hackos D., Scearce-Levie K.,
RA   Schwarz J.B.;
RT   "Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators
RT   (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.";
RL   J. Med. Chem. 59:2760-2779(2016).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=26875626; DOI=10.1016/j.neuron.2016.01.016;
RA   Hackos D.H., Lupardus P.J., Grand T., Chen Y., Wang T.M., Reynen P.,
RA   Gustafson A., Wallweber H.J., Volgraf M., Sellers B.D., Schwarz J.B.,
RA   Paoletti P., Sheng M., Zhou Q., Hanson J.E.;
RT   "Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct
RT   Modes of Action and Impacts on Circuit Function.";
RL   Neuron 89:983-999(2016).
RN   [12]
RP   INTERACTION WITH CAMK2A.
RX   PubMed=28130356; DOI=10.1523/jneurosci.2068-16.2017;
RA   Stephenson J.R., Wang X., Perfitt T.L., Parrish W.P., Shonesy B.C.,
RA   Marks C.R., Mortlock D.P., Nakagawa T., Sutcliffe J.S., Colbran R.J.;
RT   "Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and
RT   Causes ASD-Related Behaviors.";
RL   J. Neurosci. 37:2216-2233(2017).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF MET-818.
RX   PubMed=28126851; DOI=10.1124/mol.116.106781;
RA   Chen W., Tankovic A., Burger P.B., Kusumoto H., Traynelis S.F., Yuan H.;
RT   "Functional evaluation of a de novo GRIN2A mutation identified in a patient
RT   with profound global developmental delay and refractory epilepsy.";
RL   Mol. Pharmacol. 91:317-330(2017).
RN   [14] {ECO:0007744|PDB:5EWJ, ECO:0007744|PDB:5EWL, ECO:0007744|PDB:5EWM}
RP   X-RAY CRYSTALLOGRAPHY (2.76 ANGSTROMS) OF 31-394 IN COMPLEX WITH GRIN1 AND
RP   SYNTHETIC INHIBITOR IFENPRODIL, SUBUNIT, GLYCOSYLATION AT ASN-74 AND
RP   ASN-341, AND DISULFIDE BONDS.
RX   PubMed=26912815; DOI=10.1124/mol.115.103036;
RA   Stroebel D., Buhl D.L., Knafels J.D., Chanda P.K., Green M., Sciabola S.,
RA   Mony L., Paoletti P., Pandit J.;
RT   "A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-
RT   selective Antagonists.";
RL   Mol. Pharmacol. 89:541-551(2016).
RN   [15]
RP   VARIANTS ILE-18; ASN-50; VAL-271; MET-362; VAL-825; ARG-1014; SER-1026;
RP   ARG-1342; LEU-1415; PHE-1424 AND PHE-1452.
RX   PubMed=22833210; DOI=10.1038/tp.2011.52;
RG   S2D team;
RA   Tarabeux J., Kebir O., Gauthier J., Hamdan F.F., Xiong L., Piton A.,
RA   Spiegelman D., Henrion E., Millet B., Fathalli F., Joober R.,
RA   Rapoport J.L., DeLisi L.E., Fombonne E., Mottron L., Forget-Dubois N.,
RA   Boivin M., Michaud J.L., Drapeau P., Lafreniere R.G., Rouleau G.A.,
RA   Krebs M.O.;
RT   "Rare mutations in N-methyl-D-aspartate glutamate receptors in autism
RT   spectrum disorders and schizophrenia.";
RL   Transl. Psychiatry 1:E55-E55(2011).
RN   [16]
RP   VARIANT MRD6 LEU-553.
RX   PubMed=23033978; DOI=10.1056/nejmoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C.,
RA   del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G.,
RA   Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [17]
RP   VARIANT MRD6 TYR-456.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [18]
RP   INVOLVEMENT IN DEE27, VARIANTS DEE27 HIS-540; ILE-615 AND GLY-618, AND
RP   CHARACTERIZATION OF VARIANTS DEE27 HIS-540; ILE-615 AND GLY-618.
RX   PubMed=24272827; DOI=10.1002/ana.24073;
RA   Lemke J.R., Hendrickx R., Geider K., Laube B., Schwake M., Harvey R.J.,
RA   James V.M., Pepler A., Steiner I., Hortnagel K., Neidhardt J., Ruf S.,
RA   Wolff M., Bartholdi D., Caraballo R., Platzer K., Suls A., De Jonghe P.,
RA   Biskup S., Weckhuysen S.;
RT   "GRIN2B mutations in West syndrome and intellectual disability with focal
RT   epilepsy.";
RL   Ann. Neurol. 75:147-154(2014).
RN   [19]
RP   VARIANT MRD6 GLY-413, AND CHARACTERIZATION OF VARIANT MRD6 GLY-413.
RX   PubMed=24863970; DOI=10.1016/j.ymgme.2014.04.001;
RA   Adams D.R., Yuan H., Holyoak T., Arajs K.H., Hakimi P., Markello T.C.,
RA   Wolfe L.A., Vilboux T., Burton B.K., Fajardo K.F., Grahame G., Holloman C.,
RA   Sincan M., Smith A.C., Wells G.A., Huang Y., Vega H., Snyder J.P.,
RA   Golas G.A., Tifft C.J., Boerkoel C.F., Hanson R.W., Traynelis S.F.,
RA   Kerr D.S., Gahl W.A.;
RT   "Three rare diseases in one sib pair: RAI1, PCK1, GRIN2B mutations
RT   associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA
RT   receptor glutamate insensitivity.";
RL   Mol. Genet. Metab. 113:161-170(2014).
RN   [20]
RP   VARIANT MRD6 GLU-820.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
RN   [21]
RP   VARIANTS MRD6 ARG-436; PHE-461 AND HIS-696, CHARACTERIZATION OF VARIANTS
RP   MRD6 GLY-413; ARG-436; TYR-456; PHE-461; CYS-682 AND HIS-696, AND
RP   CHARACTERIZATION OF VARIANT DEE27 HIS-540.
RX   PubMed=27839871; DOI=10.1016/j.ajhg.2016.10.002;
RA   Swanger S.A., Chen W., Wells G., Burger P.B., Tankovic A., Bhattacharya S.,
RA   Strong K.L., Hu C., Kusumoto H., Zhang J., Adams D.R., Millichap J.J.,
RA   Petrovski S., Traynelis S.F., Yuan H.;
RT   "Mechanistic insight into NMDA receptor dysregulation by rare variants in
RT   the GluN2A and GluN2B agonist binding domains.";
RL   Am. J. Hum. Genet. 99:1261-1280(2016).
RN   [22]
RP   VARIANT DEE27 MET-15, AND VARIANT ALA-1439.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D., Bigoni S.,
RA   Barba C., Mari F., Montomoli M., Pisano T., Rosati A., Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
RN   [23]
RP   CHARACTERIZATION OF VARIANT MRD6 LEU-553, AND MUTAGENESIS OF PRO-553.
RX   PubMed=28095420; DOI=10.1371/journal.pgen.1006536;
RA   Ogden K.K., Chen W., Swanger S.A., McDaniel M.J., Fan L.Z., Hu C.,
RA   Tankovic A., Kusumoto H., Kosobucki G.J., Schulien A.J., Su Z., Pecha J.,
RA   Bhattacharya S., Petrovski S., Cohen A.E., Aizenman E., Traynelis S.F.,
RA   Yuan H.;
RT   "Molecular mechanism of disease-associated mutations in the pre-M1 helix of
RT   NMDA receptors and potential rescue pharmacology.";
RL   PLoS Genet. 13:E1006536-E1006536(2017).
CC   -!- FUNCTION: Component of NMDA receptor complexes that function as
CC       heterotetrameric, ligand-gated ion channels with high calcium
CC       permeability and voltage-dependent sensitivity to magnesium. Channel
CC       activation requires binding of the neurotransmitter glutamate to the
CC       epsilon subunit, glycine binding to the zeta subunit, plus membrane
CC       depolarization to eliminate channel inhibition by Mg(2+)
CC       (PubMed:8768735, PubMed:26919761, PubMed:26875626, PubMed:28126851).
CC       Sensitivity to glutamate and channel kinetics depend on the subunit
CC       composition (PubMed:8768735, PubMed:26875626). In concert with DAPK1 at
CC       extrasynaptic sites, acts as a central mediator for stroke damage. Its
CC       phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor
CC       channel activity inducing injurious Ca2+ influx through them, resulting
CC       in an irreversible neuronal death. Contributes to neural pattern
CC       formation in the developing brain. Plays a role in long-term depression
CC       (LTD) of hippocampus membrane currents and in synaptic plasticity (By
CC       similarity). {ECO:0000250|UniProtKB:Q01097,
CC       ECO:0000269|PubMed:26875626, ECO:0000269|PubMed:26919761,
CC       ECO:0000269|PubMed:28126851, ECO:0000269|PubMed:8768735}.
CC   -!- SUBUNIT: Heterotetramer. Forms heterotetrameric channels composed of
CC       two zeta subunits (GRIN1), and two epsilon subunits (GRIN2A, GRIN2B,
CC       GRIN2C or GRIN2D) (in vitro) (PubMed:8768735, PubMed:26919761,
CC       PubMed:26875626, PubMed:28126851, PubMed:26912815). Can also form
CC       heterotetrameric channels that contain at least one zeta subunit
CC       (GRIN1), at least one epsilon subunit, plus GRIN3A or GRIN3B (By
CC       similarity). In vivo, the subunit composition may depend on the
CC       expression levels of the different subunits (Probable). Found in a
CC       complex with GRIN1 and GRIN3B. Found in a complex with GRIN1, GRIN3A
CC       and PPP2CB. Interacts with PDZ domains of PATJ, DLG3 and DLG4.
CC       Interacts with HIP1 and NETO1 (By similarity). Interacts with MAGI3
CC       (PubMed:10748157). Interacts with DAPK1 (By similarity). Found in a
CC       complex with GRIN1 and PRR7 (PubMed:27458189). Interacts with PRR7
CC       (PubMed:27458189). Interacts with CAMK2A (PubMed:28130356). Interacts
CC       with ARC; preventing ARC oligomerization (By similarity). Interacts
CC       with TMEM25 (By similarity). {ECO:0000250|UniProtKB:Q00960,
CC       ECO:0000250|UniProtKB:Q01097, ECO:0000269|PubMed:10748157,
CC       ECO:0000269|PubMed:26875626, ECO:0000269|PubMed:26912815,
CC       ECO:0000269|PubMed:26919761, ECO:0000269|PubMed:27458189,
CC       ECO:0000269|PubMed:28126851, ECO:0000269|PubMed:28130356,
CC       ECO:0000269|PubMed:8768735}.
CC   -!- INTERACTION:
CC       Q13224; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-2256942, EBI-1383687;
CC       Q13224; Q12959: DLG1; NbExp=3; IntAct=EBI-2256942, EBI-357481;
CC       Q13224; P78352: DLG4; NbExp=3; IntAct=EBI-2256942, EBI-80389;
CC       Q13224; Q05586-1: GRIN1; NbExp=2; IntAct=EBI-2256942, EBI-27070564;
CC       Q13224; Q62936: Dlg3; Xeno; NbExp=4; IntAct=EBI-2256942, EBI-349596;
CC       Q13224; P31016: Dlg4; Xeno; NbExp=2; IntAct=EBI-2256942, EBI-375655;
CC       Q13224; P62139: PPP1CA; Xeno; NbExp=2; IntAct=EBI-2256942, EBI-2008988;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26875626,
CC       ECO:0000269|PubMed:26919761, ECO:0000269|PubMed:28126851,
CC       ECO:0000269|PubMed:8768735}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:Q00960}. Postsynaptic cell membrane
CC       {ECO:0000250|UniProtKB:Q00960}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:Q00960}. Late endosome
CC       {ECO:0000250|UniProtKB:Q01097}. Lysosome
CC       {ECO:0000250|UniProtKB:Q01097}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q01097}. Note=Co-localizes with the motor
CC       protein KIF17 along microtubules. {ECO:0000250|UniProtKB:Q01097}.
CC   -!- TISSUE SPECIFICITY: Primarily found in the fronto-parieto-temporal
CC       cortex and hippocampus pyramidal cells, lower expression in the basal
CC       ganglia. {ECO:0000269|PubMed:9547169}.
CC   -!- DOMAIN: A hydrophobic region that gives rise to the prediction of a
CC       transmembrane span does not cross the membrane, but is part of a
CC       discontinuously helical region that dips into the membrane and is
CC       probably part of the pore and of the selectivity filter.
CC       {ECO:0000250|UniProtKB:Q00960}.
CC   -!- PTM: Phosphorylated on tyrosine residues (By similarity).
CC       Phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor
CC       channel activity (By similarity). {ECO:0000250|UniProtKB:Q00960,
CC       ECO:0000250|UniProtKB:Q01097}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 6,
CC       with or without seizures (MRD6) [MIM:613970]: A disorder characterized
CC       by significantly below average general intellectual functioning
CC       associated with impairments in adaptive behavior and manifested during
CC       the developmental period. MRD6 additional features may include
CC       seizures, hypotonia, abnormal movements, such as dystonia, and autistic
CC       features. {ECO:0000269|PubMed:20890276, ECO:0000269|PubMed:23033978,
CC       ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:24863970,
CC       ECO:0000269|PubMed:25356899, ECO:0000269|PubMed:27839871,
CC       ECO:0000269|PubMed:28095420}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Developmental and epileptic encephalopathy 27 (DEE27)
CC       [MIM:616139]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe early-onset epilepsies characterized by refractory seizures,
CC       neurodevelopmental impairment, and poor prognosis. Development is
CC       normal prior to seizure onset, after which cognitive and motor delays
CC       become apparent. {ECO:0000269|PubMed:24272827,
CC       ECO:0000269|PubMed:27839871, ECO:0000269|PubMed:27864847}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=A chromosomal aberrations involving GRIN2B has been found
CC       in patients with intellectual disability. Translocations
CC       t(9;12)(p23;p13.1) and t(10;12)(q21.1;p13.1) with a common breakpoint
CC       in 12p13.1.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel (TC 1.A.10.1)
CC       family. NR2B/GRIN2B subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U90278; AAB49993.1; -; mRNA.
DR   EMBL; U88963; AAD00659.1; -; mRNA.
DR   EMBL; U11287; AAB60368.1; -; mRNA.
DR   EMBL; BC113618; AAI13619.1; -; mRNA.
DR   EMBL; BC113620; AAI13621.1; -; mRNA.
DR   EMBL; U28758; AAA74930.1; -; mRNA.
DR   EMBL; U28861; AAA69919.1; -; mRNA.
DR   EMBL; U28862; AAA69920.1; -; mRNA.
DR   CCDS; CCDS8662.1; -.
DR   PIR; I39066; I39066.
DR   PIR; S52086; S52086.
DR   RefSeq; NP_000825.2; NM_000834.3.
DR   RefSeq; XP_011518930.1; XM_011520628.2.
DR   RefSeq; XP_011518931.1; XM_011520629.2.
DR   RefSeq; XP_016874708.1; XM_017019219.1.
DR   PDB; 5EWJ; X-ray; 2.77 A; B/D=31-394.
DR   PDB; 5EWL; X-ray; 2.98 A; B/D=31-394.
DR   PDB; 5EWM; X-ray; 2.76 A; B/D=31-394.
DR   PDB; 7EU8; EM; 4.07 A; B/D=1-842.
DR   PDB; 7KL0; X-ray; 2.40 A; C/D=1289-1310.
DR   PDB; 7KL1; X-ray; 2.40 A; C/D=1289-1310.
DR   PDB; 7KL2; X-ray; 2.56 A; B=1289-1310.
DR   PDB; 7UIS; X-ray; 2.58 A; B=1289-1310.
DR   PDB; 7UJP; X-ray; 2.56 A; C/D=1289-1310.
DR   PDB; 7UJQ; X-ray; 2.25 A; C/D=1289-1310.
DR   PDB; 7UJR; X-ray; 1.95 A; B=1289-1310.
DR   PDB; 7UJS; X-ray; 2.75 A; B=1289-1310.
DR   PDB; 7UJT; X-ray; 2.10 A; B=1289-1310.
DR   PDBsum; 5EWJ; -.
DR   PDBsum; 5EWL; -.
DR   PDBsum; 5EWM; -.
DR   PDBsum; 7EU8; -.
DR   PDBsum; 7KL0; -.
DR   PDBsum; 7KL1; -.
DR   PDBsum; 7KL2; -.
DR   PDBsum; 7UIS; -.
DR   PDBsum; 7UJP; -.
DR   PDBsum; 7UJQ; -.
DR   PDBsum; 7UJR; -.
DR   PDBsum; 7UJS; -.
DR   PDBsum; 7UJT; -.
DR   AlphaFoldDB; Q13224; -.
DR   SMR; Q13224; -.
DR   BioGRID; 109161; 44.
DR   ComplexPortal; CPX-285; NMDA receptor complex, GluN1-GluN2B.
DR   ComplexPortal; CPX-294; NMDA receptor complex, GluN1-GluN2A-GluN2B.
DR   DIP; DIP-41002N; -.
DR   IntAct; Q13224; 20.
DR   MINT; Q13224; -.
DR   STRING; 9606.ENSP00000477455; -.
DR   BindingDB; Q13224; -.
DR   ChEMBL; CHEMBL1904; -.
DR   DrugBank; DB00659; Acamprosate.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00289; Atomoxetine.
DR   DrugBank; DB00647; Dextropropoxyphene.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB11823; Esketamine.
DR   DrugBank; DB05956; EVT-101.
DR   DrugBank; DB00949; Felbamate.
DR   DrugBank; DB13146; Fluciclovine (18F).
DR   DrugBank; DB06741; Gavestinel.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugBank; DB00874; Guaifenesin.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB08954; Ifenprodil.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB09409; Magnesium acetate tetrahydrate.
DR   DrugBank; DB09481; Magnesium carbonate.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB04896; Milnacipran.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB00418; Secobarbital.
DR   DrugBank; DB01956; Taurine.
DR   DrugBank; DB01520; Tenocyclidine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugCentral; Q13224; -.
DR   GuidetoPHARMACOLOGY; 457; -.
DR   GlyCosmos; Q13224; 7 sites, No reported glycans.
DR   GlyGen; Q13224; 7 sites.
DR   iPTMnet; Q13224; -.
DR   PhosphoSitePlus; Q13224; -.
DR   BioMuta; GRIN2B; -.
DR   DMDM; 14548162; -.
DR   jPOST; Q13224; -.
DR   MassIVE; Q13224; -.
DR   PaxDb; Q13224; -.
DR   PeptideAtlas; Q13224; -.
DR   ProteomicsDB; 59232; -.
DR   ABCD; Q13224; 1 sequenced antibody.
DR   Antibodypedia; 71655; 1452 antibodies from 48 providers.
DR   DNASU; 2904; -.
DR   Ensembl; ENST00000609686.4; ENSP00000477455.1; ENSG00000273079.7.
DR   GeneID; 2904; -.
DR   KEGG; hsa:2904; -.
DR   MANE-Select; ENST00000609686.4; ENSP00000477455.1; NM_000834.5; NP_000825.2.
DR   UCSC; uc001rbt.3; human.
DR   AGR; HGNC:4586; -.
DR   CTD; 2904; -.
DR   DisGeNET; 2904; -.
DR   GeneCards; GRIN2B; -.
DR   GeneReviews; GRIN2B; -.
DR   HGNC; HGNC:4586; GRIN2B.
DR   HPA; ENSG00000273079; Tissue enriched (brain).
DR   MalaCards; GRIN2B; -.
DR   MIM; 138252; gene.
DR   MIM; 613970; phenotype.
DR   MIM; 616139; phenotype.
DR   neXtProt; NX_Q13224; -.
DR   OpenTargets; ENSG00000273079; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   Orphanet; 589547; GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder.
DR   Orphanet; 3451; Infantile spasms syndrome.
DR   PharmGKB; PA28980; -.
DR   VEuPathDB; HostDB:ENSG00000273079; -.
DR   eggNOG; KOG1053; Eukaryota.
DR   GeneTree; ENSGT00940000155964; -.
DR   HOGENOM; CLU_002598_1_0_1; -.
DR   InParanoid; Q13224; -.
DR   OMA; KNDRYSG; -.
DR   OrthoDB; 1034721at2759; -.
DR   PhylomeDB; Q13224; -.
DR   TreeFam; TF314731; -.
DR   PathwayCommons; Q13224; -.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6794361; Neurexins and neuroligins.
DR   Reactome; R-HSA-8849932; Synaptic adhesion-like molecules.
DR   Reactome; R-HSA-9022699; MECP2 regulates neuronal receptors and channels.
DR   Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN.
DR   Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   SignaLink; Q13224; -.
DR   SIGNOR; Q13224; -.
DR   BioGRID-ORCS; 2904; 15 hits in 1150 CRISPR screens.
DR   ChiTaRS; GRIN2B; human.
DR   GeneWiki; GRIN2B; -.
DR   GenomeRNAi; 2904; -.
DR   Pharos; Q13224; Tclin.
DR   PRO; PR:Q13224; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q13224; protein.
DR   Bgee; ENSG00000273079; Expressed in buccal mucosa cell and 114 other tissues.
DR   ExpressionAtlas; Q13224; baseline and differential.
DR   Genevisible; Q13224; HS.
DR   GO; GO:0009986; C:cell surface; ISS:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:ARUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:BHF-UCL.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0098839; C:postsynaptic density membrane; IBA:GO_Central.
DR   GO; GO:0045211; C:postsynaptic membrane; TAS:ARUK-UCL.
DR   GO; GO:0097060; C:synaptic membrane; ISS:ARUK-UCL.
DR   GO; GO:0001540; F:amyloid-beta binding; NAS:ARUK-UCL.
DR   GO; GO:0016595; F:glutamate binding; ISS:UniProtKB.
DR   GO; GO:0022849; F:glutamate-gated calcium ion channel activity; IDA:UniProtKB.
DR   GO; GO:0016594; F:glycine binding; IDA:UniProtKB.
DR   GO; GO:0099507; F:ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; NAS:ARUK-UCL.
DR   GO; GO:0097553; P:calcium ion transmembrane import into cytosol; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0098976; P:excitatory chemical synaptic transmission; NAS:ARUK-UCL.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IBA:GO_Central.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISO:ComplexPortal.
DR   GO; GO:0007611; P:learning or memory; ISS:ARUK-UCL.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IBA:GO_Central.
DR   GO; GO:0098655; P:monoatomic cation transmembrane transport; ISS:ComplexPortal.
DR   GO; GO:1902951; P:negative regulation of dendritic spine maintenance; ISS:ARUK-UCL.
DR   GO; GO:2001056; P:positive regulation of cysteine-type endopeptidase activity; ISS:ARUK-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISO:ComplexPortal.
DR   GO; GO:1901216; P:positive regulation of neuron death; ISS:ARUK-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISO:ComplexPortal.
DR   GO; GO:0051290; P:protein heterotetramerization; ISS:UniProtKB.
DR   GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; ISS:ComplexPortal.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; NAS:ComplexPortal.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; NAS:ARUK-UCL.
DR   GO; GO:0045471; P:response to ethanol; IDA:UniProtKB.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IBA:GO_Central.
DR   CDD; cd06378; PBP1_iGluR_NMDA_NR2; 1.
DR   CDD; cd13718; PBP2_iGluR_NMDA_Nr2; 1.
DR   Gene3D; 3.40.50.2300; -; 2.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 3.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_Glu_rcpt_met.
DR   InterPro; IPR015683; Ionotropic_Glu_rcpt.
DR   InterPro; IPR001320; Iontro_rcpt_C.
DR   InterPro; IPR018884; NMDAR2_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR18966:SF382; GLUTAMATE RECEPTOR IONOTROPIC, NMDA 2B; 1.
DR   PANTHER; PTHR18966; IONOTROPIC GLUTAMATE RECEPTOR; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF10565; NMDAR2_C; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; Periplasmic binding protein-like I; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Chromosomal rearrangement; Cytoplasm;
KW   Cytoskeleton; Disease variant; Disulfide bond; Endosome; Epilepsy;
KW   Glycoprotein; Intellectual disability; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Lysosome; Magnesium; Membrane; Metal-binding;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Signal; Synapse; Transmembrane; Transmembrane helix; Transport; Zinc.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..1484
FT                   /note="Glutamate receptor ionotropic, NMDA 2B"
FT                   /id="PRO_0000011577"
FT   TOPO_DOM        27..557
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TRANSMEM        558..576
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TOPO_DOM        577..603
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   INTRAMEM        604..623
FT                   /note="Discontinuously helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TOPO_DOM        624..630
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TRANSMEM        631..646
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TOPO_DOM        647..817
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TRANSMEM        818..837
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   TOPO_DOM        838..1484
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   REGION          604..623
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:A7XY94"
FT   REGION          1074..1097
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1161..1194
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1271..1301
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1292..1304
FT                   /note="Interaction with DAPK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOTIF           1482..1484
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1079..1097
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1271..1291
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         127
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   BINDING         284
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   BINDING         514
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   BINDING         519
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   BINDING         690..691
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   BINDING         732
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   SITE            615
FT                   /note="Functional determinant of NMDA receptors"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         882
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         886
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   MOD_RES         917
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         962
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1039
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1058
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1061
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1064
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1109
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1133
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1155
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1255
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1259
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1303
FT                   /note="Phosphoserine; by DAPK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   MOD_RES         1474
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01097"
FT   CARBOHYD        74
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        341
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        348
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        444
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        491
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        542
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        688
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        86..321
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   DISULFID        429..456
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   DISULFID        436..457
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   DISULFID        746..801
FT                   /evidence="ECO:0000250|UniProtKB:Q00960"
FT   VARIANT         15
FT                   /note="V -> M (in DEE27; unknown pathological significance;
FT                   dbSNP:rs1057519553)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078235"
FT   VARIANT         18
FT                   /note="V -> I (in dbSNP:rs201094029)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079943"
FT   VARIANT         50
FT                   /note="I -> N (found in a patient with schizophrenia;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079944"
FT   VARIANT         271
FT                   /note="A -> V (in dbSNP:rs138098032)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079945"
FT   VARIANT         362
FT                   /note="L -> M (found in a patient with schizophrenia;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079946"
FT   VARIANT         407
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:7999784"
FT                   /id="VAR_011317"
FT   VARIANT         413
FT                   /note="E -> G (in MRD6; decreased protein abundance;
FT                   decreased localization to the cell membrane; changed
FT                   glutamate-gated calcium ion channel activity characterized
FT                   by decreased glutamate potency; dbSNP:rs527236034)"
FT                   /evidence="ECO:0000269|PubMed:24863970,
FT                   ECO:0000269|PubMed:27839871"
FT                   /id="VAR_079947"
FT   VARIANT         436
FT                   /note="C -> R (in MRD6; decreased protein abundance;
FT                   decreased localization to the cell membrane;
FT                   dbSNP:rs1565478152)"
FT                   /evidence="ECO:0000269|PubMed:27839871"
FT                   /id="VAR_079948"
FT   VARIANT         456
FT                   /note="C -> Y (in MRD6; decreased protein abundance;
FT                   decreased localization to the cell membrane; changed
FT                   glutamate-gated calcium ion channel activity characterized
FT                   by increased glutamate and glycine potency and increased
FT                   open probability; dbSNP:rs397514555)"
FT                   /evidence="ECO:0000269|PubMed:23160955,
FT                   ECO:0000269|PubMed:27839871"
FT                   /id="VAR_076764"
FT   VARIANT         461
FT                   /note="C -> F (in MRD6; decreased protein abundance;
FT                   decreased localization to the cell membrane; decreased
FT                   glutamate-gated calcium ion channel activity characterized
FT                   by decreased glutamate potency and increased glycine
FT                   potency; dbSNP:rs1949427787)"
FT                   /evidence="ECO:0000269|PubMed:27839871"
FT                   /id="VAR_079949"
FT   VARIANT         540
FT                   /note="R -> H (in DEE27; decreased protein abundance;
FT                   decreased localization to the cell membrane; increased
FT                   glutamate-gated calcium ion channel activity via an
FT                   allosteric effect which is characterized by increased
FT                   glutamate and glycine potency and increased open
FT                   probability; the mutant channel is less sensitive to
FT                   magnesium inhibition and has increased calcium permeability
FT                   compared to wild-type; dbSNP:rs672601378)"
FT                   /evidence="ECO:0000269|PubMed:24272827,
FT                   ECO:0000269|PubMed:27839871"
FT                   /id="VAR_072663"
FT   VARIANT         553
FT                   /note="P -> L (in MRD6; no effect on localization to the
FT                   cell membrane; loss of glutamate-gated calcium ion channel
FT                   activity; dbSNP:rs397514556)"
FT                   /evidence="ECO:0000269|PubMed:23033978,
FT                   ECO:0000269|PubMed:28095420"
FT                   /id="VAR_069384"
FT   VARIANT         615
FT                   /note="N -> I (in DEE27; severe phenotype with early onset
FT                   seizures; gain of function mutation; results in neuronal
FT                   hyperexcitability; the mutant channel is not inhibited by
FT                   magnesium and has increased calcium permeability compared
FT                   to wild-type; dbSNP:rs672601377)"
FT                   /evidence="ECO:0000269|PubMed:24272827"
FT                   /id="VAR_072664"
FT   VARIANT         618
FT                   /note="V -> G (in DEE27; severe phenotype with early onset
FT                   seizures; gain of function mutation; results in neuronal
FT                   hyperexcitability; the mutant channel is not inhibited by
FT                   magnesium and has increased calcium permeability compared
FT                   to wild-type; dbSNP:rs672601376)"
FT                   /evidence="ECO:0000269|PubMed:24272827"
FT                   /id="VAR_072665"
FT   VARIANT         682
FT                   /note="R -> C (in MRD6; decreased protein abundance; no
FT                   effect on localization to the cell membrane; no significant
FT                   effect on calcium ion transmembrane import into cytosol;
FT                   analysis of agonist dose-response curves for glutamate and
FT                   glycine are not consistent; dbSNP:rs387906636)"
FT                   /evidence="ECO:0000269|PubMed:20890276,
FT                   ECO:0000269|PubMed:27839871"
FT                   /id="VAR_065900"
FT   VARIANT         696
FT                   /note="R -> H (in MRD6; decreased protein abundance;
FT                   decreased localization to the cell membrane; changed
FT                   glutamate-gated calcium ion channel activity characterized
FT                   by increased glutamate and glycine potency;
FT                   dbSNP:rs1555103971)"
FT                   /evidence="ECO:0000269|PubMed:27839871"
FT                   /id="VAR_079950"
FT   VARIANT         820
FT                   /note="G -> E (in MRD6; dbSNP:rs797044849)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078647"
FT   VARIANT         825
FT                   /note="L -> V (probable disease-associated variant found in
FT                   a patient with autism spectrum disorder;
FT                   dbSNP:rs1948651813)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079951"
FT   VARIANT         1014
FT                   /note="Q -> R (found in a patient with schizophrenia;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079952"
FT   VARIANT         1026
FT                   /note="G -> S (in dbSNP:rs201963596)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079953"
FT   VARIANT         1342
FT                   /note="M -> R"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079954"
FT   VARIANT         1415
FT                   /note="S -> L (found in a patient with autism spectrum
FT                   disorder; unknown pathological significance;
FT                   dbSNP:rs201463390)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079955"
FT   VARIANT         1424
FT                   /note="L -> F (in dbSNP:rs748128078)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079956"
FT   VARIANT         1439
FT                   /note="P -> A (found in a patient with Landau-Kleffner
FT                   syndrome; unknown pathological significance;
FT                   dbSNP:rs758042475)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078236"
FT   VARIANT         1452
FT                   /note="S -> F (found in a patient with schizophrenia;
FT                   unknown pathological significance; dbSNP:rs756790727)"
FT                   /evidence="ECO:0000269|PubMed:22833210"
FT                   /id="VAR_079957"
FT   MUTAGEN         553
FT                   /note="P->R: Changed glutamate-gated calcium ion channel
FT                   activity characterized by increased glutamate and glycine
FT                   potency and slowed response rise time and deactivation time
FT                   course."
FT                   /evidence="ECO:0000269|PubMed:28095420"
FT   MUTAGEN         818
FT                   /note="M->V: Increased glutamate and glycine agonist
FT                   potency."
FT                   /evidence="ECO:0000269|PubMed:28126851"
FT   CONFLICT        434
FT                   /note="V -> A (in Ref. 3; AAD00659)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        745
FT                   /note="G -> A (in Ref. 5; AAA69920)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        773
FT                   /note="K -> N (in Ref. 5; AAA69920/AAA74930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        796
FT                   /note="W -> C (in Ref. 5; AAA69920/AAA74930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        888
FT                   /note="T -> P (in Ref. 5; AAA69920/AAA74930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        902
FT                   /note="L -> V (in Ref. 5; AAA69920/AAA74930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        920..921
FT                   /note="SA -> RP (in Ref. 1; AAB60368)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        958
FT                   /note="L -> S (in Ref. 5; AAA69920/AAA74930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        980..982
FT                   /note="VYQ -> DHY (in Ref. 5; AAA69920)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1056
FT                   /note="I -> M (in Ref. 5; AAA69920)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1167
FT                   /note="V -> I (in Ref. 2; AAB49993)"
FT                   /evidence="ECO:0000305"
FT   STRAND          34..44
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           47..50
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          62..73
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           78..91
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          94..100
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           107..119
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          123..127
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           128..131
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          143..147
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           150..164
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          168..173
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           179..191
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          193..195
FT                   /evidence="ECO:0007829|PDB:5EWL"
FT   STRAND          198..204
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           215..221
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          226..232
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           234..246
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          255..258
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           260..263
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          278..282
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   TURN            284..286
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           289..311
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:5EWJ"
FT   HELIX           324..327
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   HELIX           336..339
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          355..359
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          362..367
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          373..379
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          384..387
FT                   /evidence="ECO:0007829|PDB:5EWM"
FT   STRAND          1304..1306
FT                   /evidence="ECO:0007829|PDB:7UJR"
SQ   SEQUENCE   1484 AA;  166367 MW;  40AEB12BE6E50CEF CRC64;
     MKPRAECCSP KFWLVLAVLA VSGSRARSQK SPPSIGIAVI LVGTSDEVAI KDAHEKDDFH
     HLSVVPRVEL VAMNETDPKS IITRICDLMS DRKIQGVVFA DDTDQEAIAQ ILDFISAQTL
     TPILGIHGGS SMIMADKDES SMFFQFGPSI EQQASVMLNI MEEYDWYIFS IVTTYFPGYQ
     DFVNKIRSTI ENSFVGWELE EVLLLDMSLD DGDSKIQNQL KKLQSPIILL YCTKEEATYI
     FEVANSVGLT GYGYTWIVPS LVAGDTDTVP AEFPTGLISV SYDEWDYGLP ARVRDGIAII
     TTAASDMLSE HSFIPEPKSS CYNTHEKRIY QSNMLNRYLI NVTFEGRNLS FSEDGYQMHP
     KLVIILLNKE RKWERVGKWK DKSLQMKYYV WPRMCPETEE QEDDHLSIVT LEEAPFVIVE
     SVDPLSGTCM RNTVPCQKRI VTENKTDEEP GYIKKCCKGF CIDILKKISK SVKFTYDLYL
     VTNGKHGKKI NGTWNGMIGE VVMKRAYMAV GSLTINEERS EVVDFSVPFI ETGISVMVSR
     SNGTVSPSAF LEPFSADVWV MMFVMLLIVS AVAVFVFEYF SPVGYNRCLA DGREPGGPSF
     TIGKAIWLLW GLVFNNSVPV QNPKGTTSKI MVSVWAFFAV IFLASYTANL AAFMIQEEYV
     DQVSGLSDKK FQRPNDFSPP FRFGTVPNGS TERNIRNNYA EMHAYMGKFN QRGVDDALLS
     LKTGKLDAFI YDAAVLNYMA GRDEGCKLVT IGSGKVFAST GYGIAIQKDS GWKRQVDLAI
     LQLFGDGEME ELEALWLTGI CHNEKNEVMS SQLDIDNMAG VFYMLGAAMA LSLITFICEH
     LFYWQFRHCF MGVCSGKPGM VFSISRGIYS CIHGVAIEER QSVMNSPTAT MNNTHSNILR
     LLRTAKNMAN LSGVNGSPQS ALDFIRRESS VYDISEHRRS FTHSDCKSYN NPPCEENLFS
     DYISEVERTF GNLQLKDSNV YQDHYHHHHR PHSIGSASSI DGLYDCDNPP FTTQSRSISK
     KPLDIGLPSS KHSQLSDLYG KFSFKSDRYS GHDDLIRSDV SDISTHTVTY GNIEGNAAKR
     RKQQYKDSLK KRPASAKSRR EFDEIELAYR RRPPRSPDHK RYFRDKEGLR DFYLDQFRTK
     ENSPHWEHVD LTDIYKERSD DFKRDSVSGG GPCTNRSHIK HGTGDKHGVV SGVPAPWEKN
     LTNVEWEDRS GGNFCRSCPS KLHNYSTTVT GQNSGRQACI RCEACKKAGN LYDISEDNSL
     QELDQPAAPV AVTSNASTTK YPQSPTNSKA QKKNRNKLRR QHSYDTFVDL QKEEAALAPR
     SVSLKDKGRF MDGSPYAHMF EMSAGESTFA NNKSSVPTAG HHHHNNPGGG YMLSKSLYPD
     RVTQNPFIPT FGDDQCLLHG SKSYFFRQPT VAGASKARPD FRALVTNKPV VSALHGAVPA
     RFQKDICIGN QSNPCVPNNK NPRAFNGSSN GHVYEKLSSI ESDV
//
